Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Cue Biopharma (CUE – Research Report) today and set a price target of $8.00. The company’s shares closed last Friday at $2.19.
Tenthoff covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Crispr Therapeutics AG, and Arrowhead Pharmaceuticals. According to TipRanks, Tenthoff has an average return of 8.0% and a 40.16% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cue Biopharma with a $8.00 average price target.
See today’s best-performing stocks on TipRanks >>
Based on Cue Biopharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.1 million and a GAAP net loss of $11.01 million. In comparison, last year the company earned a revenue of $68 thousand and had a GAAP net loss of $10.96 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cue Biopharma (CUE) Company Description:
Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.
